Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

[1]  D. Faller,et al.  Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. , 2001, Current opinion in oncology.

[2]  J. Wingard,et al.  Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab , 2001, Bone Marrow Transplantation.

[3]  R. Porcher,et al.  Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Grillo‐López.  Rituximab: an insider's historical perspective. , 2000, Seminars in oncology.

[5]  R. Busuttil,et al.  The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. , 2000, Transplantation.

[6]  P. Nowell,et al.  The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Ledbetter,et al.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer Immunology, Immunotherapy.

[8]  Zhensheng Liu,et al.  CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.

[9]  H. Riess,et al.  Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? , 2000, Transplantation.

[10]  M. Hoeper,et al.  Treatment of lympho-proliferative disease with rituximab , 2000, The Lancet.

[11]  J. Rabkin,et al.  Successful Treatment of Aggressive Post Transplant Lymphoproliferative Disorder using Rituximab , 2000, Leukemia & lymphoma.

[12]  T. Starzl,et al.  Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. , 1999, Transplantation.

[13]  E. Kieff,et al.  Epstein-barr virus-induced posttransplant lymphoproliferative disorders , 1999 .

[14]  R. Gascoyne,et al.  Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation , 1999, The Lancet.

[15]  D. Hébert,et al.  Lymphoproliferative disorders after organ transplantation in children. , 1999, Transplantation.

[16]  M. Peuchmaur,et al.  Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders , 1998, The Lancet.

[17]  N. Harris,et al.  Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. , 1997, Seminars in diagnostic pathology.

[18]  J. Camardo,et al.  Rapamycin (sirolimus, rapamune) , 1995, Current opinion in nephrology and hypertension.

[19]  S. Muthukkumar,et al.  RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS , 1995, Transplantation.

[20]  J. Blenis,et al.  Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. , 1995, Cellular immunology.

[21]  G. Mills,et al.  Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. , 1995, Cancer research.

[22]  A. Fischer,et al.  Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. , 1991, The New England journal of medicine.

[23]  A. Craft,et al.  Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. , 1988, The New England journal of medicine.

[24]  Simmons Rl,et al.  Immunosuppression and malignant neoplasms. , 1970, The New England journal of medicine.

[25]  T. Starzl,et al.  Clotting changes, including disseminated intravascular coagulation, during rapid renal-homograft rejection. , 1970, The New England journal of medicine.

[26]  J. H. Harrison,et al.  Five Years' Experience in Renal Transplantation with Immunosuppressive Drugs: Survival, Function, Complications, and the Role of Lymphocyte Depletion by Thoracic Duct Fistula , 1968, Annals of surgery.

[27]  T. Starzl,et al.  Orthotopic homotransplantation of the human liver. , 1968 .

[28]  S. Sacchi,et al.  Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. , 2001, Critical reviews in oncology/hematology.

[29]  V. Leblond,et al.  Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  E. Cesarman,et al.  Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. , 1995, Blood.